- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Senate approves Jane Henney to lead FDA
The U.S. Senate heeded the recommendation of the Senate Labor and Human Resources Committee and voted to confirm Jane Henney, M.D., as the commissioner of the Food and Drug Administration.
WASHINGTON - The U.S. Senate heeded the recommendation of the Senate Labor and Human Resources Committee and voted to confirm Jane Henney, M.D., as the commissioner of the Food and Drug Administration.
"The discussions I have had with many members of the Senate over the past several weeks have reaffirmed my belief that the FDA serves as a non-partisan arbiter of public policy, with decisions that are grounded in science and law," Henney said.
"As I have made clear in prior statements, my priority as commissioner will be to implement the FDA Modernization Act and to strengthen the agency's scientific base to ensure the best science guides the critical decisions that need to be made," Henney said.
Secretary Shalala said of Henney: "Jane Henney is a seasoned professional who brings substantial management skills and a depth of experience to the agency. The FDA safeguards food and drugs from the factory to the store shelf to every medicine cabinet and kitchen cupboard in America. Dr. Henney has the judgment to carry out that vital responsibility in a changing health marketplace, and I know that she will forge new and productive relationships with consumers and the industry." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
